chartexchange

Gyre Therapeutics Reports Third Quarter 2026 and Year-to-Date Financial Results with Business Updates

GlobeNewswire Inc. | Nov 5, 2026 4:07 PM EST

Q3 2026 revenue of $32.9 million; GAAP basic EPS: $(0.04)

Read original article